title: Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.
abstract: BACKGROUND
  Recent studies suggested that IL28B polymorphisms may affect rapid and sustained virological response rates in HCV patients infected with genotype 2 or 3.
  
  
  OBJECTIVE
  To assess the role of IL28B polymorphisms on the virological response in HCV-2 and -3 patients.
  
  
  METHODS
  We performed meta-analysis of studies evaluating the impact of rs12979860 and rs8099917 polymorphisms on rapid and sustained virological response in HCV-2 or -3 patients.
  
  
  RESULTS
  Twenty-three studies involving 3042 patients were included. The first meta-analysis evaluated the impact of rs12979860 polymorphism and included 1963 patients. When compared with rs12979860 CT/TT patients, CC patients had a higher rapid virological response rate (mean difference: 12.9%, 95% CI: 6.5-19.4%, P < 0.001) and a higher sustained virological response rate (mean difference: 4.9%, 95% CI: 0.1-9.8%, P = 0.046). The second meta-analysis evaluated the impact of rs8099917 polymorphism and included 2246 patients. When compared with rs8099917 TG/GG patients, TT patients had a higher rapid virological response rate (mean difference: 14.8%, 95% CI: 7.2-22.4%, P < 0.001) and a higher sustained virological response rate (mean difference: 5.5%, 95% CI: 0.4-10.6%, P = 0.033). When considering only patients treated for 24 weeks, results were unchanged. No potential sources of between-study heterogeneity were identified.
  
  
  CONCLUSIONS
  Favourable IL28B polymorphisms are associated with higher rapid and sustained virological response rates in HCV-2 and -3 patients. However, as the impact on a sustained response is very limited, it is unlikely that IL28B polymorphisms provide additional predictive value when considering other predictors of a sustained response.
authors: Service de Gastroentérologie et d'Hépatopancréatologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
authors: J
authors: J
authors: Schreiber
authors: C
authors: C
authors: Moreno
authors: B Garcia
authors: BG
authors: Garcia
authors: A
authors: A
authors: Louvet
authors: E
authors: E
authors: Trepo
authors: J
authors: J
authors: Henrion
authors: D
authors: D
authors: Thabut
authors: P
authors: P
authors: Mathurin
authors: P
authors: P
authors: Deltenre
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D016896:Treatment Outcome; D019562:Viral Load; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda